Menu Search
Equities

Inhibrx Biosciences Inc

INBX:NSQ

Inhibrx Biosciences Inc

Actions
  • Price (USD)14.12
  • Today's Change0.14 / 1.00%
  • Shares traded42.76k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 20:41 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Inhibrx Biosciences Inc's revenues fell -17.88% from 2.19m to 1.80m. a loss of 145.23m to a larger loss of 241.36m.
Gross margin--
Net profit margin94,778.95%
Operating margin95,253.12%
Return on assets552.15%
Return on equity1,065.91%
Return on investment637.71%
More ▼

Cash flow in USDView more

In 2023, Inhibrx Biosciences Inc did not generate a significant amount of cash. Cash Flow from Financing totalled 201.96m or 11,220.06% of revenues. In addition the company used 193.31m for operations while cash used for investing totalled 4.59m.
Cash flow per share47.37
Price/Cash flow per share0.123
Book value per share12.33
Tangible book value per share12.33
More ▼

Balance sheet in USDView more

Inhibrx Biosciences Inc appears to have little financial risk as the company holds a substantial amount of cash on its books with little or no debt.
Current ratio4.70
Quick ratio--
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.